Galileo – Biotech Innovation Fund RM USD

Reference Data

ISIN LU2462149217
Valor Number
Bloomberg Global ID
Fund Name Galileo – Biotech Innovation Fund RM USD
Fund Provider IPConcept (Luxemburg) S.A. Zürich, Switzerland
Phone: +352 260248-1
E-Mail: info.lu@ipconcept.com
Web: www.ipconcept.com
Fund Provider IPConcept (Luxemburg) S.A.
Representative in Switzerland IPConcept (Schweiz) AG
Zürich
Phone: +41 044 224 32 09
Distributor(s) Bellecapital AG
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund charges a transaction fee (contribution towards expenses incurred in the investment of new assets)
Redemption Condition The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel)
Investment Strategy *** The objective of the investment policy for the sub-fund is to achieve an appropriate level of growth in the sub-fund currency while taking the investment risk into account. The sub-fund is actively managed. The composition of the portfolio is determined by the Fund Manager solely in accordance with the criteria laid down in the investment objectives / the investment policy, is regularly reviewed and, if necessary, adjusted. The sub-fund is not managed using an index as a benchmark.
Peculiarities

Fund Prices

Current Price * 112.34 USD 07.10.2025
Previous Price * 112.31 USD 06.10.2025
52 Week High * 116.46 USD 12.11.2024
52 Week Low * 65.91 USD 09.04.2025
NAV * 112.34 USD 07.10.2025
Issue Price * 112.34 USD 07.10.2025
Redemption Price * 112.34 USD 07.10.2025
Closing Price *
Indicative Minimum Price
Fund Assets *** 36,552,352
Unit/Share Assets *** 15,919
Trading Information SIX

Performance

YTD Performance +20.00% 30.12.2024
07.10.2025
YTD Performance (in CHF) +5.50% 30.12.2024
07.10.2025
1 month +20.60% 08.09.2025
07.10.2025
3 months +36.22% 07.07.2025
07.10.2025
6 months +60.37% 07.04.2025
07.10.2025
1 year +3.10% 07.10.2024
07.10.2025
2 years -25.65% 11.03.2024
07.10.2025
3 years - -
5 years - -

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Krystal Biotech Inc 9.73%
Arcellx Inc 8.91%
Alnylam Pharmaceuticals Inc 5.90%
Vertex Pharmaceuticals Inc 5.68%
BioNTech SE ADR 4.30%
Regeneron Pharmaceuticals Inc 4.20%
Sarepta Therapeutics Inc 3.07%
Moderna Inc 2.97%
Stoke Therapeutics Inc 2.74%
CARsgen Therapeutics Holdings Ltd Ordinary Shares 2.38%
Last data update 31.03.2025

Cost / Risk

TER *** 2.07%
TER date *** 30.06.2025
Performance Fee ***
PTR
Max. Management Fee *** 1.60%
Ongoing Charges *** 2.08%
SRRI ***
SRRI date *** 30.09.2025

Breakdowns

Equity Countries ***

Equity Sectors ***

Bond Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)